Studies on the Possible Application of BNCT to Thyroid Cancer

  • Mario A. Pisarev
  • Maria A. Dagrosa
  • Guillermo J. Juvenal


Thyroid cancer may occur as a differentiated or an undifferentiated or anaplasic form. The differentiated forms, such as papillary or follicular carcinomas, are in general of a relatively benign prognosis. Most if not all still have a normal uptake of iodine, and therefore surgical thyroidectomy is completed with a therapeutic dose of 131I. In many cases, these forms are well controlled and complete remission of the tumor is obtained. In other instances, the prognosis is not so good. The undifferentiated (UTC) form or the recurrence of some differentiated forms of this pathology has lost their capability to concentrate radioiodine, and therefore the therapeutic dose of this halogen is useless. These last forms are very aggressive and have a fatal outcome in rather a short time after their diagnosis. As a consequence, new treatments are being explored in order to offer these patients a better future. Thanks to the advances in the knowledge of their molecular biology, new chemotherapeutic compounds have been developed and are currently being studied in several clinical trials. Besides, we have started some years ago the study of the possibility of the application of BNCT to the treatment of these pathologies [1, 2].


Thyroid Cancer Neutron Beam Differentiate Thyroid Cancer Relative Biological Effectiveness Follicular Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The original studies from our laboratory were supported by grants from the National Research Council (CONICET), the National Agency for Science and Technology (FONCyT), the University of Buenos Aires, and the Atomic Energy Commission. All authors are established researchers from CONICET.


  1. 1.
    Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715–726PubMedCrossRefGoogle Scholar
  2. 2.
    Chandrakanth A, Ashok RS et al (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors and treatment approaches. Ann Surg Oncol 13:1–12CrossRefGoogle Scholar
  3. 3.
    Dagrosa MA, Viaggi M, Kreimann E, Garavaglia R, Farías S, Agote M, Cabrini RL, Juvenal G, Pisarev MA (2002) Selective biodistribution of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy (BNCT). Thyroid 12(1):7–12PubMedCrossRefGoogle Scholar
  4. 4.
    Viaggi M, Dagrosa MA, Gangitano D, Belli C, Larripa I, Cabrini R, Pisarev M, Juvenal G (2003) A new animal model for human undifferentiated thyroid carcinoma. Thyroid 13:529–536PubMedCrossRefGoogle Scholar
  5. 5.
    Mishima Y, Imahori Y, Honda C, Hiratsuka J, Ueda S, Ido T (1997) In vivo diagnosis of human melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol 33:163–169PubMedCrossRefGoogle Scholar
  6. 6.
    Wittig A, Sauerwein WA, Coderre JA (2000) Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res 153:173–180PubMedCrossRefGoogle Scholar
  7. 7.
    Dagrosa MA, Viaggi M, Longhino J, Calzetta O, Cabrini R, Edreira M, Juvenal G, Pisarev M (2003) Experimental application of boron neutron capture therapy (BNCT) to undifferentiated thyroid carcinoma (UTC). Int J Radiat Oncol Biol Phys 57(4):1084–1092PubMedCrossRefGoogle Scholar
  8. 8.
    Rydberg B (1996) Clusters of DNA damage induced by ionizing radiation: formation of short DNA fragments. II. Experimental detection. Radiat Res 145:200–209PubMedCrossRefGoogle Scholar
  9. 9.
    Kahl SB, Koo MS (1992) Synthesis and properties of tetrakiscarborane-carboxylate esters of 2, 4-bis (−dihydroxyethyl) deuteroporphyrin IX. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in neutron capture therapy for cancer. Plenum Press, New York, pp 223–226CrossRefGoogle Scholar
  10. 10.
    Dagrosa MA, Viaggi M, Jiménez Rebagliati R, Batistoni D, Kahl SB, Juvenal G, Pisarev M (2005) Biodistribution of boron compounds in an animal model of undifferentiated thyroid cancer for boron neutron capture therapy. Mol Pharm 2(2):152–156CrossRefGoogle Scholar
  11. 11.
    Dagrosa MA, Thomasz L, Longhino J, Perona M, Calzetta O, Blaumann H, Jiménez Rebagliati R, Cabrini RL, Kahl SB, Juvenal GJ, Pisarev MA (2007) Optimization of the application of boron neutron capture therapy (BNCT) to the treatment of undifferentiated thyroid cancer (UTC). Int J Radiat Oncol Biol Phys 69(4):1059–1066PubMedCrossRefGoogle Scholar
  12. 12.
    Agote M, Viaggi M, Kreimann E, Krawiec L, Dagrosa MA, Juvenal GJ, Pisarev MA (2001) Influence of nicotinamide on the radiosensitivity of normal and goitrous thyroid in the rat. Thyroid 11:1005–1009CrossRefGoogle Scholar
  13. 13.
    Horsman MR, Siemann DW, Chaplin DJ et al (1997) Nicotinamide as a radiosensitizer in tumor and normal tissues: the importance of drug dose and timing. Radiother Oncol 45:167–174PubMedCrossRefGoogle Scholar
  14. 14.
    Dagrosa MA, Viaggi M, Jimenez Rebagliati R, Castillo VA, Batistoni D, Cabrini RL, Castiglia S, Juvenal GJ, Pisarev MA (2004) Biodistribution of p-borophenylalanine (BPA) in dogs with spontaneous undifferentiated thyroid carcinoma (UTC). Appl Radiat Isot 61(5):911–915PubMedCrossRefGoogle Scholar
  15. 15.
    Dagrosa MA, Chung Y, Riley K, Binns P, Kahl S, Pisarev M, Coderre J (2006) Compound biological effectiveness (CBE) factors in human undifferentiated thyroid cancer (UTC). Advances in Neutron Capture Therapy. Proceedings of ICNCT 12, Takamatsu, Kagawa, 2006, pp 157–160Google Scholar
  16. 16.
    Dagrosa M, Crivello M, Thorp S, Perona M, Pozzi E, Casal M, Cabrini R, Kahl S, Juvenal G, Pisarev M (2008) Radiobiological studies in a human cell line of undifferentiated thyroid cancer. Proceedings of 13 ICNCT, Florence, 2008, pp 337–340Google Scholar
  17. 17.
    Wittig A, Sheu Y, Kaiser GM, Lang S, Jöckel H, Moss R, Stecher-Rasmussen F, Rassow J, Colette L, Sauerwein W (2008) New indications for BNCT? Results from the EORTC trial 11001. Proceedings of 13 ICNCT, Florence, 2008, pp 39–42Google Scholar
  18. 18.
    Hiratsuka J, Morita N, Aihara T, Imajo Y, Maruhashi A, Ono K (2006) First clinical trial of boron neutron capture therapy for thyroid cancer. Advances in Neutron Capture Therapy. Proceedings of ICNCT 12, Takamatsu, Kagawa, 2006, pp 7–9Google Scholar
  19. 19.
    Dagrosa MA, Carpano M, Perona M, Thomasz L, Nievas S, Cabrini R, Juvenal G, Pisarev M (2011) Studies for the application of boron neutron therapy to the treatment of differentiated thyroid cancer. Appl Radiat Isot 69:1752–1755CrossRefGoogle Scholar
  20. 20.
    Perona M, Pontigia O, Carpano M, Thomasz L, Thorp S, Pozzi E, Simian M, Kahl SB, Juvenal G, Pisarev N, Dagrosa A (2011) Un Vitro studies of cellular response to DNA damage induced by boron neutron capture therapy. Appl Radiat Isot 69:1732–1738CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Mario A. Pisarev
    • 1
    • 2
  • Maria A. Dagrosa
    • 1
    • 3
  • Guillermo J. Juvenal
    • 1
    • 3
  1. 1.Department of RadiobiologyNational Atomic Energy CommissionBuenos AiresArgentina
  2. 2.Department of Human BiochemistryUniversity of Buenos Aires, School of MedicineBuenos AiresArgentina
  3. 3.National Research Council of ArgentinaBuenos AiresArgentina

Personalised recommendations